Quick Answer
Aardvark Therapeutics, Inc. reported Operating Income Loss of -$62.73 million for the year ending 2025.
- Aardvark Therapeutics, Inc. showed a decrease of -175.3% in Operating Income Loss from 2024 to 2025.
- This data is from Aardvark Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$2.17 million | Q2 2024: -$6.07 million | Q3 2024: -$5.09 million | Q1 2025: -$10.47 million | Q2 2025: -$15.85 million | Q3 2025: -$17.70 million.
- Historical annual values: Fiscal year 2025: -$62.73 million | Fiscal year 2024: -$22.79 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: